ESC Premium Access

Effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the short-term prognosis of COVID-19 infection

Presentation

About the speaker

Doctor Laura Esteban-Lucia

Fundacion Jimenez Diaz University Hospital, Madrid (Spain)
0 follower

57 more presentations in this session

Efficacy of propafenone vs. amiodarone in pharmacological cardioversion of recent-onset atrial fibrillation to sinus rhythm: a pooled meta-analysis of 9 randomized controlled trials

Speaker: Doctor J. Borovac (Split, HR)

Thumbnail

The prevalence and safety of direct oral anticoagulants in patients with non-atrial fibrillation associated intra-cardiac thrombus

Speaker: Doctor A. KANWAL (Valhalla, US)

Thumbnail

Efficiency and safety of the modified protocol for cardioversion of atrial fibrillation using the antiarrhythmic drug niferidil. First results of clinical use.

Speaker: Doctor K. Dzaurova (Moscow, RU)

Thumbnail

The effect of glucagon-like peptide-1 receptor agonists on 24-hour ambulatory blood pressure: a meta-analysis

Speaker: Mrs A. Boulmpou (Thessaloniki, GR)

Thumbnail

Risk of death with sodium-glucose co-transporter-2 inhibitors across the hallmark cardiovascular and renal outcome trials: an updated meta-analysis

Speaker: Mrs A. Boulmpou (Thessaloniki, GR)

Thumbnail

Access the full session

Pharmacology and pharmacotherapy e-posters

Speakers: Doctor L. Esteban-Lucia, Doctor J. Borovac, Doctor A. KANWAL, Doctor K. Dzaurova, Mrs A. Boulmpou...
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

Open Access

Dual therapy, triple therapy, or single-pill combination: still underused or already part of physicians' mindsets?

29 August 2021

ESC Premium Access

Prasugrel or clopidogrel in patients with acute coronary syndromes at high thrombotic risk: results from the PROMETHEUS study

28 August 2021

ESC Premium Access

Hospitalized patients with hypertension and moderate COVID-19 benefit from continuing ACEIs and ARBs: Insights from the BRACE CORONA trial

27 August 2021

This platform is supported by

logo Novo Nordisk